Colorectal Neoplasm Clinical Trials

85 recruitingLast updated: June 18, 2026

There are 85 actively recruiting colorectal neoplasm clinical trials across 41 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Barcelona, Spain, New York, New York, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Colorectal Neoplasm Trials at a Glance

85 actively recruiting trials for colorectal neoplasm are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Not Applicable with 20 trials, with the heaviest enrollment activity in Barcelona, New York, and Houston. Lead sponsors running colorectal neoplasm studies include Cancer Research UK, Eli Lilly and Company, and Janssen Research & Development, LLC.

Browse colorectal neoplasm trials by phase

Treatments under study

About Colorectal Neoplasm Clinical Trials

Looking for clinical trials for Colorectal Neoplasm? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colorectal Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colorectal Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 85 trials

Recruiting

Early Detection of Advanced Adenomas and Colorectal Cancer

Colorectal, CancerColorectal NeoplasmsColorectal Adenocarcinoma+15 more
City of Hope Medical Center2,000 enrolled6 locationsNCT06342440
Recruiting
Not Applicable

Early Feeding Versus Delayed Feeding After Colorectal Endoscopic Submucosal Dissection

Colorectal NeoplasmsEndoscopic Submucosal Dissection
Pusan National University Hospital204 enrolled5 locationsNCT06805123
Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

CholangiocarcinomaPancreas CancerColorectal Neoplasms+2 more
National Cancer Institute (NCI)1,800 enrolled1 locationNCT01915225
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 1

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

Colorectal Neoplasms
Janssen Research & Development, LLC380 enrolled9 locationsNCT07107230
Recruiting
Phase 3

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Colorectal NeoplasmsNeoplasm MetastasisGastrointestinal Neoplasms+2 more
Sun Yat-sen University280 enrolled1 locationNCT03303495
Recruiting
Phase 3

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Colorectal NeoplasmsNeoplasms by SiteGastrointestinal Neoplasms+7 more
Pfizer800 enrolled228 locationsNCT07222800
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled30 locationsNCT07213791
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled30 locationsNCT07114601
Recruiting
Phase 3

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled381 locationsNCT05253651
Recruiting
Not Applicable

Impact of SMS Messaging on Participation in Colorectal Cancer Screening.

Colorectal NeoplasmsEarly Detection of Cancer
Corporacion Parc Tauli10,084 enrolled1 locationNCT07628998
Recruiting
Phase 1Phase 2

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Advanced Solid TumorNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Blueprint Medicines Corporation265 enrolled1 locationNCT07629960
Recruiting

AP-NOSES: A Prospective Multicentre Registry of Natural Orifice Specimen Extraction in Minimally Invasive Colorectal Surgery

Colorectal NeoplasmsIncisional Hernia
Singapore General Hospital800 enrolled1 locationNCT07615036
Recruiting
Not Applicable

PRIORITY-CONNECT 2 Trial

Colorectal, CancerColorectal Neoplasms
Surgical Outcomes Research Centre (SOuRCe)564 enrolled31 locationsNCT06976710
Recruiting
Phase 1

First in Human Study of AZD9592 in Solid Tumors

Carcinoma, Non-Small Cell LungColorectal NeoplasmsHead and Neck Neoplasms+1 more
AstraZeneca403 enrolled51 locationsNCT05647122
Recruiting
Phase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Colorectal NeoplasmsGastrointestinal Neoplasms
Janssen Research & Development, LLC220 enrolled11 locationsNCT06663319
Recruiting
Phase 1Phase 2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816